Episode

E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)

Podcast
The Evidence Based Rheumatology Podcast
Published
Nov 12, 2025
Duration seconds
1143
Processing state
not_requested
Canonical source
https://msputman.podbean.com/e/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild/
Audio
https://mcdn.podbean.com/mf/web/mrj3wqag58vv2vti/e128.mp3
JSON
/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild
Markdown
/podcast/the-evidence-based-rheumatology-podcast-1130175/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out! Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643